CLINICAL TRIAL: TRIAL OF EARLY AGGRESSIVE TREATMENT IN JUVENILE IDIOPATHIC ARTHR

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 该研究希望，在多关节幼年特发性关节炎症状开始后6个月内开始积极治疗将比目前的治疗更有效，在6个月内实现非活动性疾病和12个月的临床缓解。 治疗组A将接受甲氨蝶呤、安慰剂Enbrel和安慰剂泼尼松龙。 治疗组B接受甲氨蝶呤、恩布雷和泼尼松龙治疗。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The study hopes that starting aggressive therapy within 6 months after the symptoms of polyarticular juvenile idiopathic arthritis starts will be more effective than current treatment in achieving inactive disease by 6 months and clinical remission by 12 months. Treatment group A will receive methotrexate placebo Enbrel and placebo prednisolone. Treatment group B will receive methotrexate, Enbrel and Prednisolone.